Definium Therapeutics - GAD Phase 3 Results

We previously wrote about the psychedelic company Definium. The company released top-line phase 3 clinical results for GAD (Generalized Anxiety Disorder), from their trial named VOYAGE this morning. The other psychedelic company attempting to address this unmet need is Helus Pharma, who already released phase 2a clinical data earlier this year, with psychedelic deuterated DMT. Although it's difficult to compare clinical data from two different trials, below is Helus Pharma's phase 2a (6 and 24 Weeks) along side Definium's phase 2b and just released phase 3 results. 

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes only, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.